Study title: A 6-week open label cross-over study with 2 different daily doses of Minirin® oral lyophilisate (120 µg and 240 µg) and 2 different daily doses of Minirin® tablet (0.2 mg and 2 x 0.2 mg) in children and adolescents with primary nocturnal enuresis (PNE)
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Behavior and Behavior Mechanisms [F01] | |||||
Brands: Please see report | |||||
MAH holders: Please see report | |||||
Assessment: | |||||
Active substance: DESMOPRESSIN | |||||
ATC code: | |||||
Document link: Desmopressin_ FE992026 CS022.pdf | |||||
Document date: 2011-09-05 | |||||
Study number: FE992026 CS022 | |||||
EudraCT number: | |||||
Scope of study: Clinical | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | Y | - |